Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
NCT ID: NCT07290140
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
300 participants
INTERVENTIONAL
2026-03-01
2031-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
• Treatment with the Airiver ESSpand DCB and ESS
Subjects will have ESSpand DCB dilation of the ESS treated sinuses
No interventions assigned to this group
Treatment with ESS
Subjects will have ESS treatment at target sinuses
ESS
traditional ESS treatment of diseased sinuses.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Airiver ESSpand DCB
The investigational procedure will be ESSpand DCB dilation of all surgically treated sinuses, including the resected ethmoid sinus cavities.
Note: Prior to randomization to the investigational procedure, all subjects will undergo traditional ESS of their diseased sinuses.
ESS
traditional ESS treatment of diseased sinuses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed diagnosis of CRS per the 2021 "International Consensus Statement on Allergy and Rhinology: Rhinosinusitis" definition.
3. Radiographic evidence of bilateral ethmoid disease on CT taken 6 months or less prior to study index procedure and at least 6 months after any prior ESS or nasal surgery, polypectomy, balloon sinus dilation, etc. as applicable
4. Radiographic evidence of bilateral frontal sinus and/or frontal sinus outflow tract disease
5. Baseline SNOT-22 score ≥ 30
6. Has failed previous medical treatment and is an appropriate candidate for primary or revision ESS of bilateral ethmoid sinuses and bilateral frontal/frontal sinus outflow tract
7. Willing and able to provide written informed consent
8. Willing and able to comply with all protocol follow up visits and assessments
Exclusion Criteria
2. Antrochoanal polyps
3. Previous complete middle turbinate resection
4. Clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on CT scan, necrotic sinus tissue)
5. History of prior lamina dehiscence or cerebrospinal fluid (CSF) leak in skull-based dehiscence
6. Concurrent condition requiring active chemotherapy and/or immunotherapy management
7. Subjects whose symptoms are too severe to undergo ESS (e.g., temperature \>102.5F or extra-sinus manifestations, such as orbital cellulitis; dental or facial or brain abscess; cavernous vein thrombosis; or altered mental status
8. History of complications from prior ESS or balloon dilation procedure (e.g., CSF leak or injury to the skull base or orbital injury)
9. History of primary ciliary dyskinesia
10. Oral-steroid dependent conditions such as chronic obstructive pulmonary disease (COPD) or other conditions
11. Have evidence of significant baseline mucosal injury, ulceration, or erosion (e.g., exposed cartilage, perforation) on nasal examination
12. Acute purulent nasal infection or upper respiratory tract infection, including but not limited to acute bacterial rhinosinusitis (ABRS), acute rhinosinusitis (ARS), or COVID -19 within 2 weeks before the baseline visit.
13. Allergy or hypersensitivity to paclitaxel or structurally related compounds.
14. Subject has taken biologic drugs in the 6 months leading up to the screening visit or who expect to take biologics in the next 24 months.
15. Subject has taken oral corticosteroids in the 30 days leading up to their baseline appointment.
16. Subject who plans to undergo posterior nasal nerve ablation in the next 24 months.
17. Subject has a history of inability to tolerate nasal endoscopy
18. Concurrent medical condition that would affect the investigator's ability to evaluate the subject's condition or that could compromise subject safety, such as severe COPD, severe asthma
19. Pregnant or planning to become pregnant during the first 12 months of enrollment in the study
20. Subject who has undergone a nasal/sinus surgery including but not limited to ESS, polypectomy, septoplasty, turbinoplasty, balloon sinus dilation, placement of steroid releasing implants, posterior nasal nerve ablation in the 6 months prior to the baseline appointment.
21. Previous Draf III frontal sinus surgery or a study index procedure ESS is expected to be or is a Draf III sinus surgery.
22. Subject whose index procedure did not include bilateral ethmoid ESS and bilateral frontal ESS
23. Subject whose expected study index procedure includes steroid releasing implants or non-resorbable nasal packing/stents.
24. Subject whose study index procedure is aborted for any reason
25. Life expectancy \<2 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Airiver Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noem Cohen, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Rodney Schlosser, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Airiver Medical
Brooklyn Park, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Operation Director
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR3056
Identifier Type: -
Identifier Source: org_study_id